Ligand's royalty-based model generates structurally high gross margins (95.0% in 2026Q2) and revenue growth (33.7% YoY), but the recent $1.1B debt-funded acquisition has elevated leverage (D/E 1.17) and introduces integration risk. The company's dependence on ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue surged 33.7% YoY in 2026Q2 to $63.7M with gross margin at 95.0%, but operating margin of 13.5% trails peers due to elevated SG&A and R&D costs, while net income of $48.5M was inflated by non-operating gains.
Ligand invests in groundbreaking medicines, funding clinical development and commercialization of high-value programs to improve and extend lives globally.
LGND is actively traded with real-time stock prices, quotes, and financial overviews available for investors.
The company supports the development and commercialization of high-value biopharmaceutical programs, enhancing its pipeline potential.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $2.37+17.9% vs $2.01 | $64M+3.9% vs $61M |
Q2 2026 May 14, 2026 | $1.63-11.4% vs $1.84 | $52M-12.5% vs $59M |
Q1 2026 Feb 26, 2026 | $2.02+38.4% vs $1.46 | $60M+7.3% vs $56M |
Q4 2025 Nov 6, 2025 | $3.09+56.9% vs $1.97 | $115M+96.5% vs $59M |
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments an.
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.
Benchmark LGND against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ligand Pharmaceuticals Incorporated (LGND)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $302.96 | $6.07B | 49.42 | 60.4% | 46.42% | 13.47% | — | |
| $14.26 | $1.97B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $94.13 | $4.54B | 15.44 | 5.91% | 33.21% | 49.73% | — | |
| $57.16 | $25.34B | 31.76 | 5.06% | 32.15% | 8.35% | — | |
| $3.38 | $234.55M | -1.07 | 105.77% | -311.11% | -33.22% | — |
Ligand Pharmaceuticals Incorporated (LGND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ligand Pharmaceuticals Incorporated (LGND) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 14, 2026·SEC
Jun 25, 2026·SEC
Get notified when LGND posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ligand Pharmaceuticals Incorporated (LGND) stock FAQ — growth, dividends, profitability & financials explained
Ligand Pharmaceuticals Incorporated (LGND) reported $290.5M in revenue for fiscal year 2025. This represents a 690% increase from $36.8M in 1996.
Ligand Pharmaceuticals Incorporated (LGND) grew revenue by 60.4% over the past year. This is strong growth.
Yes, Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $197.2M in net income for fiscal year 2025 (46.4% net margin).
Ligand Pharmaceuticals Incorporated (LGND) has a return on equity (ROE) of 13.5%. This is reasonable for most industries.
Ligand Pharmaceuticals Incorporated (LGND) generated $131.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
